

Benjamin E Gewurz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4294320/publications.pdf>

Version: 2024-02-01

54
papers

3,333
citations

186265
28
h-index

168389
53
g-index

61
all docs

61
docs citations

61
times ranked

4316
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral Subversion of the Immune System. <i>Annual Review of Immunology</i> , 2000, 18, 861-926.	21.8	764
2	Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. <i>Nature Microbiology</i> , 2018, 3, 1-8.	13.3	151
3	The NF- κ B Genomic Landscape in Lymphoblastoid B Cells. <i>Cell Reports</i> , 2014, 8, 1595-1606.	6.4	147
4	Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth. <i>Cell Host and Microbe</i> , 2015, 17, 205-216.	11.0	146
5	Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation. <i>Cell Metabolism</i> , 2019, 30, 539-555.e11.	16.2	119
6	CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. <i>Cell Host and Microbe</i> , 2017, 21, 580-591.e7.	11.0	113
7	Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. <i>Cell Research</i> , 2020, 30, 950-965.	12.0	111
8	Epstein-Barr Virus LMP1-Mediated Oncogenicity. <i>Journal of Virology</i> , 2017, 91, .	3.4	103
9	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	9.4	103
10	SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. <i>Nature Communications</i> , 2021, 12, 1676.	12.8	102
11	Genome-wide siRNA screen for mediators of NF- κ B activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2467-2472.	7.1	100
12	The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. <i>Cell Host and Microbe</i> , 2017, 22, 561-573.e4.	11.0	89
13	Regulation of p53 and Rb Links the Alternative NF- κ B Pathway to EZH2 Expression and Cell Senescence. <i>PLoS Genetics</i> , 2014, 10, e1004642.	3.5	83
14	A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells. <i>Cell Reports</i> , 2017, 19, 1479-1493.	6.4	83
15	RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes. <i>Journal of Virology</i> , 2019, 93, .	3.4	71
16	TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation. <i>PLoS Pathogens</i> , 2015, 11, e1004890.	4.7	67
17	MYC Controls the Epstein-Barr Virus Lytic Switch. <i>Molecular Cell</i> , 2020, 78, 653-669.e8.	9.7	67
18	CRISPR/Cas9 Screens Reveal Requirements for Host Cell Sulfation and Fucosylation in Bacterial Type III Secretion System-Mediated Cytotoxicity. <i>Cell Host and Microbe</i> , 2016, 20, 226-237.	11.0	64

#	ARTICLE	IF	CITATIONS
19	N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. <i>EMBO Reports</i> , 2021, 22, e50128.	4.5	59
20	Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival. <i>PLoS Pathogens</i> , 2019, 15, e1008030.	4.7	57
21	Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4751-4756.	7.1	44
22	Canonical NF- κ B Activation Is Essential for Epstein-Barr Virus Latent Membrane Protein 1 TES2/CTAR2 Gene Regulation. <i>Journal of Virology</i> , 2011, 85, 6764-6773.	3.4	43
23	Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11612-11617.	7.1	43
24	IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18448-18453.	7.1	42
25	Down-regulation of MHC class I antigen presentation by HCMV; lessons for tumor immunology. <i>Immunological Investigations</i> , 2000, 29, 97-100.	2.0	39
26	Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. <i>Blood</i> , 2020, 135, 1870-1881.	1.4	39
27	Human herpesvirus 6 encephalitis. <i>Current Infectious Disease Reports</i> , 2008, 10, 292-9.	3.0	38
28	US2, a Human Cytomegalovirus-encoded Type I Membrane Protein, Contains a Non-cleavable Amino-terminal Signal Peptide. <i>Journal of Biological Chemistry</i> , 2002, 277, 11306-11313.	3.4	33
29	CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. <i>Journal of Virology</i> , 2020, 94, .	3.4	33
30	DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. <i>Nature Microbiology</i> , 2020, 5, 1051-1063.	13.3	32
31	Epstein-Barr virus BNRF1 destabilizes SMC5/6 cohesin complexes to evade its restriction of replication compartments. <i>Cell Reports</i> , 2022, 38, 110411.	6.4	31
32	CRISPR/Cas9-Mediated Genome Editing in Epstein-Barr Virus-Transformed Lymphoblastoid B-Cell Lines. <i>Current Protocols in Molecular Biology</i> , 2018, 121, 31.12.1-31.12.23.	2.9	27
33	Epigenetic control of the Epstein-Barr lifecycle. <i>Current Opinion in Virology</i> , 2022, 52, 78-88.	5.4	21
34	CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions. <i>Viruses</i> , 2018, 10, 55.	3.3	20
35	CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival. <i>Blood</i> , 2021, 138, 2216-2230.	1.4	20
36	EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 1076-1088.	5.3	19

#	ARTICLE	IF	CITATIONS
37	Epstein-Barr virus latency programs dynamically sensitize B cells to ferroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118300119.	7.1	19
38	CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. <i>Cell Reports</i> , 2019, 28, 1307-1322.e8.	6.4	18
39	Epigenetic crossroads of the Epstein-Barr virus B-cell relationship. <i>Current Opinion in Virology</i> , 2018, 32, 15-23.	5.4	17
40	Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation. <i>MBio</i> , 2020, 11, .	4.1	17
41	Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival. <i>MBio</i> , 2021, 12, e0153021.	4.1	16
42	Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300. <i>Journal of Virology</i> , 2018, 92, .	3.4	15
43	Epstein-Barr latent membrane protein 1 transformation site 2 activates NF- κ B in the absence of NF- κ B essential modifier residues 133-224 or 373-419. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18103-18108.	7.1	12
44	Genome-wide CRISPR-based gene knockout screens reveal cellular factors and pathways essential for nasopharyngeal carcinoma. <i>Journal of Biological Chemistry</i> , 2019, 294, 9734-9745.	3.4	12
45	DNA-Damage Control: Claspin Destruction Turns off the Checkpoint. <i>Current Biology</i> , 2006, 16, R932-R934.	3.9	11
46	Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma. <i>Frontiers in Immunology</i> , 2021, 12, 651013.	4.8	11
47	Epstein-Barr virus oncoprotein-driven B cell metabolism remodeling. <i>PLoS Pathogens</i> , 2022, 18, e1010254.	4.7	11
48	TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity. <i>Journal of Virology</i> , 2019, 93, .	3.4	10
49	HIV and the breast. <i>Aids Reader</i> , 2005, 15, 392-6, 399-402.	0.3	9
50	Abstract 65: Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. , 2021, , .		6
51	The nuclear lamina binds the EBV genome during latency and regulates viral gene expression. <i>PLoS Pathogens</i> , 2022, 18, e1010400.	4.7	6
52	Herpesvirus evasion of T-cell immunity. , 2007, , 1117-1136.		4
53	Modulating Gene Expression in Epstein-Barr Virus (EBV)-Positive B Cell Lines with CRISPRa and CRISPRi. <i>Current Protocols in Molecular Biology</i> , 2018, 121, 31.13.1-31.13.18.	2.9	4
54	700...Increasing MHC-I expression to potentiate immune checkpoint blockade therapy. , 2021, 9, A728-A728.		0